<p>US President Donald Trump is receiving an experimental treatment of synthetic antibodies for Covid-19, his doctor said Friday, and is "fatigued but in good spirits."</p>.<p>Trump received a single dose of Regeneron's antibody cocktail, according to a letter issued by White House physician Sean Conley.</p>.<p>The treatment is undergoing clinical trials but hasn't received any form of regulatory approval.</p>.<p>"He's being evaluated by a team of experts, and together we'll be making recommendations to the President and First Lady in regards to next best steps," Conley said.</p>.<p>Trump -- who has repeatedly cast doubt on the seriousness of the pandemic -- first announced in an overnight tweet that he and First Lady Melania Trump, 50, had tested positive and were going into quarantine.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/international/world-news-politics/who-wishes-fierce-critic-donald-trump-speedy-recovery-896530.html" target="_blank"><strong>WH</strong>O wishes 'fierce critic' Donald Trump speedy recovery</a></strong></p>.<p>Earlier this week, Regeneron announced results from one of its early-stage trials which showed its drug, which is infused intravenously, reduced viral load and recovery time in non-hospitalized Covid-19 patients.</p>.<p>"We have begun discussing our findings with regulatory authorities while continuing our ongoing trial," said George Yancopoulos, the company's president and chief scientific officer on Tuesday.</p>.<p>The US biotech firm is concurrently running late-stage trials for hospitalized Covid-19 patients and for the drug's potential use as a prophylaxis.</p>.<p>Antibodies are infection-fighting proteins made by the immune system that can bind to particular structures on the surfaces of pathogens and prevent them from invading cells.</p>.<p>Vaccines work by teaching the body to make its own antibodies, while scientists are also testing ready-made antibodies from the blood of recovered patients, called convalescent plasma.</p>.<p>But it is not possible to make convalescent plasma a mass treatment.</p>.<p>Researchers can also comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture it at scale.</p>.<p>Regeneron's experimental Covid-19 drug, called REGN-COV2, is a combination of two antibodies, referred to as a "cocktail."</p>.<p>The idea is it will have a better chance at working if the virus mutates in order to evade the blocking action of a single antibody.</p>.<p>Last year, a triple-antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.</p>
<p>US President Donald Trump is receiving an experimental treatment of synthetic antibodies for Covid-19, his doctor said Friday, and is "fatigued but in good spirits."</p>.<p>Trump received a single dose of Regeneron's antibody cocktail, according to a letter issued by White House physician Sean Conley.</p>.<p>The treatment is undergoing clinical trials but hasn't received any form of regulatory approval.</p>.<p>"He's being evaluated by a team of experts, and together we'll be making recommendations to the President and First Lady in regards to next best steps," Conley said.</p>.<p>Trump -- who has repeatedly cast doubt on the seriousness of the pandemic -- first announced in an overnight tweet that he and First Lady Melania Trump, 50, had tested positive and were going into quarantine.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/international/world-news-politics/who-wishes-fierce-critic-donald-trump-speedy-recovery-896530.html" target="_blank"><strong>WH</strong>O wishes 'fierce critic' Donald Trump speedy recovery</a></strong></p>.<p>Earlier this week, Regeneron announced results from one of its early-stage trials which showed its drug, which is infused intravenously, reduced viral load and recovery time in non-hospitalized Covid-19 patients.</p>.<p>"We have begun discussing our findings with regulatory authorities while continuing our ongoing trial," said George Yancopoulos, the company's president and chief scientific officer on Tuesday.</p>.<p>The US biotech firm is concurrently running late-stage trials for hospitalized Covid-19 patients and for the drug's potential use as a prophylaxis.</p>.<p>Antibodies are infection-fighting proteins made by the immune system that can bind to particular structures on the surfaces of pathogens and prevent them from invading cells.</p>.<p>Vaccines work by teaching the body to make its own antibodies, while scientists are also testing ready-made antibodies from the blood of recovered patients, called convalescent plasma.</p>.<p>But it is not possible to make convalescent plasma a mass treatment.</p>.<p>Researchers can also comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture it at scale.</p>.<p>Regeneron's experimental Covid-19 drug, called REGN-COV2, is a combination of two antibodies, referred to as a "cocktail."</p>.<p>The idea is it will have a better chance at working if the virus mutates in order to evade the blocking action of a single antibody.</p>.<p>Last year, a triple-antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.</p>